BTW
DGX icon

Boston Trust Walden’s Quest Diagnostics DGX Stock Holding History

Boston Trust Walden’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.45M Buy
30,425
+35
+0.1% +$6.87K 0.05% 221
2026
Q1 		$5.96M Buy
30,390
+1,541
+5% +$299K 0.05% 231
2025
Q4 		$5.01M Sell
28,849
-745
-3% -$136K 0.04% 224
2025
Q3 		$5.64M Sell
29,594
-53,026
-64% -$9.41M 0.04% 220
2025
Q2 		$14.8M Sell
82,620
-2,105
-2% -$366K 0.11% 189
2025
Q1 		$14.3M Buy
84,725
+11,795
+16% +$1.94M 0.1% 188
2024
Q4 		$11M Buy
72,930
+18,435
+34% +$2.87M 0.08% 197
2024
Q3 		$8.46M Buy
54,495
+10
+0% +$1.49K 0.06% 210
2024
Q2 		$7.46M Sell
54,485
-1,125
-2% -$154K 0.06% 215
2024
Q1 		$7.4M Buy
55,610
+445
+0.8% +$57.7K 0.05% 213
2023
Q4 		$7.61M Sell
55,165
-795
-1% -$105K 0.06% 205
2023
Q3 		$6.82M Sell
55,960
-200
-0.4% -$26.6K 0.06% 210
2023
Q2 		$7.89M Buy
56,160
+550
+1% +$75.8K 0.06% 209
2023
Q1 		$7.87M Sell
55,610
-7,965
-13% -$1.14M 0.07% 211
2022
Q4 		$9.95M Buy
63,575
+15,675
+33% +$2.25M 0.09% 201
2022
Q3 		$5.88M Buy
47,900
+4,755
+11% +$626K 0.06% 219
2022
Q2 		$5.74M Sell
43,145
-1,080
-2% -$147K 0.05% 223
2022
Q1 		$6.05M Sell
44,225
-3,375
-7% -$470K 0.05% 230
2021
Q4 		$8.23M Buy
47,600
+14,150
+42% +$2.15M 0.07% 222
2021
Q3 		$4.86M Buy
33,450
+2,000
+6% +$293K 0.04% 237
2021
Q2 		$4.15M Buy
31,450
+12,650
+67% +$1.66M 0.04% 246
2021
Q1 		$2.41M Sell
18,800
-125
-0.7% -$15.4K 0.02% 252
2020
Q4 		$2.25M Sell
18,925
-50
-0.3% -$6.09K 0.02% 259
2020
Q3 		$2.17M Sell
18,975
-150
-0.8% -$17.7K 0.03% 262
2020
Q2 		$2.18M Sell
19,125
-200
-1% -$21.2K 0.03% 261
2020
Q1 		$1.55M Hold
19,325
– – 0.02% 265
2019
Q4 		$2.06M Sell
19,325
-1,575
-8% -$164K 0.02% 267
2019
Q3 		$2.24M Sell
20,900
-125
-0.6% -$12.8K 0.03% 258
2019
Q2 		$2.14M Sell
21,025
-30
-0.1% -$2.88K 0.03% 267
2019
Q1 		$1.89M Buy
21,055
+325
+2% +$28.2K 0.03% 274
2018
Q4 		$1.73M Sell
20,730
-70
-0.3% -$6.56K 0.03% 273
2018
Q3 		$2.24M Buy
20,800
+1,800
+9% +$197K 0.03% 268
2018
Q2 		$2.09M Hold
19,000
– – 0.03% 271
2018
Q1 		$1.91M Buy
19,000
+100
+0.5% +$10.2K 0.03% 271
2017
Q4 		$1.86M Hold
18,900
– – 0.03% 277
2017
Q3 		$1.77M Hold
18,900
– – 0.03% 285
2017
Q2 		$2.1M Hold
18,900
– – 0.03% 270
2017
Q1 		$1.85M Buy
18,900
+5,550
+42% +$529K 0.03% 269
2016
Q4 		$1.23M Sell
13,350
-800
-6% -$69K 0.02% 287
2016
Q3 		$1.2M Sell
14,150
-700
-5% -$58.8K 0.02% 285
2016
Q2 		$1.21M Sell
14,850
-900
-6% -$68.5K 0.02% 285
2016
Q1 		$1.13M Sell
15,750
-170
-1% -$11.4K 0.02% 289
2015
Q4 		$1.13M Sell
15,920
-1,850
-10% -$124K 0.02% 278
2015
Q3 		$1.09M Sell
17,770
-3,600
-17% -$252K 0.02% 286
2015
Q2 		$1.55M Sell
21,370
-1,230
-5% -$90.8K 0.02% 269
2015
Q1 		$1.74M Sell
22,600
-1,025
-4% -$73.4K 0.03% 254
2014
Q4 		$1.58M Buy
23,625
+1,300
+6% +$82K 0.02% 262
2014
Q3 		$1.35M Buy
22,325
+4,000
+22% +$246K 0.02% 263
2014
Q2 		$1.08M Buy
+18,325
New +$1.07M 0.02% 275

Other funds holding DGX

AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
ECSS
Eurizon Capital SGR SpA Milan $37.3B AUM
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return
AIM
Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Boston Trust Walden's DGX Position: Q2 2026 in Review

Boston Trust Walden increased its Quest Diagnostics (DGX) stake by 0.12% in Q2 2026, buying an estimated $6.87K and bringing the position to 30,425 shares worth $6.45M. The position accounts for 0.05% of the portfolio, ranked #221.

Boston Trust Walden first reported a position in DGX in Q2 2014 and has held it in 49 quarters since. The position peaked at $14.8M in Q2 2025. 396 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Boston Trust Walden held 30,425 shares of Quest Diagnostics worth $6.45M as of Q2 2026.
  • Boston Trust Walden bought 35 Quest Diagnostics shares in Q2 2026, an estimated $6.87K.
  • Quest Diagnostics made up 0.05% of Boston Trust Walden's portfolio in Q2 2026, its #221 holding.
  • Boston Trust Walden first reported a position in Quest Diagnostics in Q2 2014 and has held it in 49 quarters since.
  • Boston Trust Walden's Quest Diagnostics position peaked at $14.8M in Q2 2025.
  • 396 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Boston Trust Walden's 13F filing for Q2 2026, filed 24 Jul 2026.